Biopharma M&A: Year in Review, Ripples Ahead
PharmExec
MARCH 10, 2023
While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.
59 
Let's personalize your content